In 1998, Clay co-founded Seattle Genetics. It was a time when cancer treatments were dominated by chemotherapies that didn’t differentiate between killing cancer cells and normal cells. His vision was to improve the lives of people with cancer by developing targeted therapies to treat major unmet needs.

A scientist by training, Clay built Seattle Genetics on a foundation of scientific innovation, rigorous research and drug development practices as well as a passion for helping patients. He has guided the company to its current leadership position in the field of antibody-drug conjugates (ADCs) and in the 2011 FDA approval of our first ADC product, ADCETRIS® (brentuximab vedotin). Under a collaboration with Takeda Pharmaceutical Company, ADCETRIS is now a global brand that is approved in 70 countries. Seattle Genetics is also advancing a diverse pipeline of proprietary ADCs for the treatment of cancer.

Under Clay’s leadership, Seattle Genetics has entered in to multiple strategic licenses for our ADC technology, including with Astellas, Genentech (Roche), AbbVie, and GlaxoSmithKline, that have generated more than $400 million to date. Clay has also led Seattle Genetics’ capital-raising activities, securing more than $1.8 billion through public and private financings, including the company’s initial public offering in 2001.

Year joined:

1998 as co-founder

Experience:

Bristol-Myers Squibb Pharmaceutical Research Institute

National Institutes of Health, National Cancert Institute

Awards:

2013 University of Maryland Alumnus of the Year for Computer, Math and Natural Sciences

2012 Pacific Northwest Ernst & Young Entrepreneur of the Year

Publications/Patents:

Author on more than 70 publications

Holds 15 patents

Education:

Ph.D., Genetics, George Washington University

B.S., Zoology, University of Maryland

Boards:

Director, Ultragenyx Pharmaceutical

Director, Alder BioPharmaceuticals

Director, Washington Roundtable

Srinivas Akkaraju, M.D., Ph.D., has served as a one of our directors since July 2003.  Dr. Akkaraju has a strong scientific background coupled with extensive experience in private equity and venture capital investing from his work at J.P. Morgan, Panorama Capital, New Leaf Venture Partners, Sofinnova Ventures, and Samsara BioCapital. This combination allows for Dr. Akkaraju to thoroughly understand our technology and provide strong business and strategic expertise.

Recent experience:

  • Samasara BioCapital
    • Founder and Managing General Partner (2017-present)
  • Sofinnova Ventures
    • General Partner (2013-2016)
  • New Leaf Venture Partners
    • Managing Director (2009-2013)

Other public company boards:

  •  Intercept Pharmaceuticals, Inc.
  • Syros Pharmaceuticals, Inc.
  • Aravive, Inc.

Education:

  • M.D. and a Ph.D. in Immunology, Stanford University
  • B.S. in Biochemistry and Computer Science, Rice University

Felix J. Baker, Ph.D., has served as a Director of Seattle Genetics since July 2003 and as our lead independent director since February 2005. As a board member and investor in many successful biotechnology companies, Dr. Baker is able to draw on his experience and vision in investing in and building companies to add significant value to Board of Directors discussions and company strategy.

Recent experience:

  • Baker Bros. Advisors LP
    • Founder and Co-Managing Member (2000-present)

Other public company boards:

  • Alexion Pharmaceuticals, Inc.
  • Kiniksa Pharmaceuticals, Ltd.
  • Kodiak Sciences Inc.

Education:

  • B.S. and a Ph.D. in Immunology from Stanford University, where he also completed two years of medical school

David W. Gryska joined our Board of Directors in March 2005. He has years of experience as Chief Financial Officer at Incyte Corporation, Celgene Corporation, Scios, Inc., and Cardiac Pathways Corporation. He brings to the Board valuable and relevant experience as a senior financial executive at life sciences and biotechnology companies engaged in financings, global expansion and other strategic transactions. He also has extensive knowledge of accounting principles and financial reporting rules and regulations, tax compliance, and oversight of the financial reporting processes of several large, publicly-traded corporations, which assists Mr. Gryska in fulfilling his duties as chair of our Audit Committee.

Recent experience:

  • Incyte Corporation
    • Executive Vice President and Chief Financial Officer (2014-2018; retired)
  • Myrexis, Inc.
    • Chief Operating Officer and Interim Chief Executive Officer (2012)
  • Celgene Corporation
    • Senior Vice President and Chief Financial Officer (2006-2010)

 Other public company boards:

  •  PDL BioPharma, Inc.
  • Aerie Pharmaceuticals, Inc.

Education:

  • M.B.A. from Golden Gate University
  • B.A. in Accounting and Finance, Loyola University

Marc E. Lippman, M.D., has served as a Director of Seattle Genetics since June 2000. Dr. Lippman’s extensive experience in treating patients and conducting oncology research at the National Cancer Institute and at the medical schools of the University of Miami, the University of Michigan and Georgetown University provides an important patient perspective and focus on innovation in our development of targeted oncology therapies. Dr. Lippman has authored more than 400 peer-reviewed publications and one of the standard texts on breast cancer.

Recent experience:

  • Georgetown University Medical Center’s Lombardi Comprehensive Cancer Center
    • Professor of Oncology (2018-present)
  • University of Miami Leonard M. Miller School of Medicine
    • Kathleen and Stanley Glaser Professor of Medicine and Chairman of the Department of Medicine (2017-2018)
    • Deputy Director of the Sylvester Comprehensive Cancer Center (2008-2017)

Education:

  • M.D. from Yale where he was elected to Alpha Omega Alpha
  • B.A., magna cum laude, Cornell

John A. Orwin joined the Seattle Genetics Board of Directors in January 2014. He has many years of experience as a senior executive at leading pharmaceutical and biotechnology companies, including Atreca, Inc., Relypsa, Inc., Affymax, Inc., Genentech, Inc., and Johnson & Johnson. This gives him a strong understanding of the biotechnology industry and the challenges we must meet to continue developing and commercializing our product candidates.

Recent experience:

  • Atreca, Inc.
    • President and Chief Executive Officer (2018-present)
  • Relypsa, Inc., now an affiliate of Vifor Pharma AG
    • Chief Executive Officer (2013-2017)
  • Affymax, Inc.
    • Board member (2011-2014)
    • Chief Executive Officer (2011-2013)
    • President and Chief Operating Officer (2010-2011)
  • Genentech, Inc, now a member of the Roche Group
    • Vice President and then Senior Vice President of the BioOncology Business Unit (2005-2010)

Other public company boards:

  • Atreca, Inc.
  • Retrophin, Inc.

Alpna Seth, Ph.D. joined our Board of Directors in March 2018. Dr. Seth has over 20 years of global experience in the biotechnology industry. Having held a range of leadership roles around the globe, Dr. Seth brings a breadth of experience in drug development, commercial, international operations, and general management.

Recent experience:

  • Proneurotech Inc.
    • Chief Executive Officer and President (2019-present)
  • Vir Biotechnology, Inc.
    • Chief Operating Officer (2017-2019)
  • Biogen, Inc.
    • Senior Vice President and Global Head of the Biosimilars Global Business Unit (2014-2017)
    • Range of leadership roles in business development, drug development and commercial (1998-2014)

Other public company boards:

  • Bio-Techne Corporation

Education:

  • Ph.D. in Biochemistry and Molecular Biology, University of Massachusetts Medical School
    • Conducted her post-doctoral research at Harvard University in Immunology and Structural Biology, both as a Howard Hughes Medical Institute Fellow
  • 2002 graduate of the Advanced Management Program at Harvard Business School

Nancy A. Simonian, M.D. joined our Board of Directors in March 2012. As a current and former senior executive of several other biotechnology companies, including Syros Pharmaceuticals, Inc., Millennium Pharmaceuticals, Inc. and Biogen, Dr. Simonian possesses a strong understanding of the biotechnology industry and the development and commercialization of our product candidates. Her knowledge of late-stage product development, as former Chief Medical Officer of Millennium Pharmaceuticals, Inc., and her understanding of patient perspectives, as a medical doctor, bring important insights to our Board of Directors.

Recent experience:

  • Syros Pharmaceuticals, Inc.
    • Chief Executive Officer (2012-present)
  • Millennium Pharmaceuticals, Inc., an affiliate of The Takeda Oncology Company
    • Chief Medical Officer (2006-2011)

Other public company boards:

  • Evelo Biosciences
  • Syros Pharmaceuticals

Education:

  • M.D. from the University of Pennsylvania Medical School
  • B.A. in Biology from Princeton University

Daniel G. Welch has served as a Director since June 2007. Mr. Welch’s global commercial background and strong senior executive experience at a wide range of biotechnology companies, including previously serving as Chairman and Chief Executive Officer of two publicly-traded biotechnology companies, InterMune, Inc. and Triangle Pharmaceuticals, Inc. gives him insight into strategy and planning for a biopharmaceutical company that is valuable to our senior management and our Board of Directors.

Recent experience:

  • Sofinnova Ventures
    • Executive Partner (2015-2018; retired)
  • InterMune, Inc.
    • Chief Executive Officer and President (2003-2014)
    • Chairman of the Board (2007-2014)

Other public company boards:

  • Intercept Pharmaceuticals, Inc.
  • Ultragenyx Pharmaceuticals, Inc. (Chairman of the Board)

Education:

  • M.B.A. from the University of North Carolina
  • B.A. from the University of Miami